Abstract
Disease Outcomes With Ublituximab in Participants With Highly Active Disease: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis (P6-3.002)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have